Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection
M Megna, C Patruno, MR Bongiorno… - Journal of …, 2022 - Taylor & Francis
Background Some biologics for psoriasis, especially anti-tumor necrosis factor (TNF)-α
therapies, may re-activate latent tuberculosis (TBC) infection with consequent morbidity and …
therapies, may re-activate latent tuberculosis (TBC) infection with consequent morbidity and …
[HTML][HTML] Efficacy and safety of secukinumab in patients with plaque psoriasis and latent tuberculosis
S Ribero, M Licciardello, P Quaglino… - Case Reports in …, 2019 - karger.com
Upon the association of biologic treatments with reactivation of latent tuberculosis infection
(LTBI), screening for Mycobacterium tuberculosis infection and anti-tuberculosis …
(LTBI), screening for Mycobacterium tuberculosis infection and anti-tuberculosis …
A propensity score-matched study on the changes of TB status and TB-IGRA values in patients with psoriasis with latent TB receiving secukinumab
Y Xiao, W Mi, J Wang, D Wen, Y Wang, Y Gu… - Dermatology and …, 2023 - Springer
Introduction The utilization of biologics in patients with psoriasis with latent tuberculosis
infection (LTBI) has garnered significant attention. Although the tuberculosis (TB) safety …
infection (LTBI) has garnered significant attention. Although the tuberculosis (TB) safety …
Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis
BE Elewski, JW Baddley, AA Deodhar… - JAMA …, 2021 - jamanetwork.com
Importance Approximately one-quarter of the global population have latent tuberculosis
infection (LTBI), and tuberculosis (TB) is accountable for more than 1.5 million deaths …
infection (LTBI), and tuberculosis (TB) is accountable for more than 1.5 million deaths …
The tuberculosis positive conversion rate among psoriasis patients treated with adalimumab and secukinumab: a single-center retrospective study in China
Y Xiao, H Chen, Q Zou, Y Wang, Y Gu, J Wang… - Dermatology and …, 2022 - Springer
Introduction The tuberculosis (TB) positive conversion rate among psoriasis patients who
received biologics has been reported worldwide, particularly in regions with low TB risk …
received biologics has been reported worldwide, particularly in regions with low TB risk …
In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque …
M Galluzzo, S D'Adamio, D Silvaggio… - Expert Opinion on …, 2020 - Taylor & Francis
Background: There is limited long-term, real-world evidence on the efficacy and safety in
patients with plaque psoriasis treated with secukinumab. We present results at 136 weeks in …
patients with plaque psoriasis treated with secukinumab. We present results at 136 weeks in …
Long‐term continuation with secukinumab in psoriasis: association with patient profile and initial psoriasis clearance
L Ferrières, MP Konstantinou… - Clinical and …, 2019 - academic.oup.com
Background There are limited data regarding the long‐term continuation with biological
therapy for patients with psoriasis. In particular, the reasons for secukinumab discontinuation …
therapy for patients with psoriasis. In particular, the reasons for secukinumab discontinuation …
Safety in moderate‐to‐severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti‐tuberculosis treatments concomitantly: results from …
Background Patients treated with tumour necrosis factor (TNF) inhibitors are at risk of new‐
onset tuberculosis (TB) or reactivation of latent tuberculosis infection (LTBI). Association …
onset tuberculosis (TB) or reactivation of latent tuberculosis infection (LTBI). Association …
Hepatitis virus reactivation in patients with psoriasis treated with secukinumab in a real-world setting of hepatitis B or hepatitis C infection
M Megna, C Patruno, MR Bongiorno… - Clinical Drug …, 2022 - Springer
Abstract Background and Objective Biologics for psoriasis, especially anti-tumor necrosis
factor-α therapies, may reactivate hepatitis B virus (HBV) or hepatitis C virus (HCV) …
factor-α therapies, may reactivate hepatitis B virus (HBV) or hepatitis C virus (HCV) …
Is chemoprophylaxis necessary for all latent tuberculosis infection patients receiving IL‐17 inhibitors? A cohort study
D Shu, Z Zhang, EY Zhou, X Ma… - Dermatologic …, 2020 - Wiley Online Library
The tuberculosis (TB) burden is high in China, with a 32% prevalence of latent tuberculosis
infection (LTBI) in Beijing. Screening for LTBI and the chemoprophylaxis of positive patients …
infection (LTBI) in Beijing. Screening for LTBI and the chemoprophylaxis of positive patients …
相关搜索
- secukinumab in patients latent tuberculosis
- patients with psoriasis tuberculosis reactivation
- tuberculosis infection lack of reactivation
- secukinumab treatment tuberculosis reactivation
- patient profile secukinumab in psoriasis
- plaque psoriasis latent tuberculosis
- plaque psoriasis treatment with secukinumab
- effectiveness and safety secukinumab for psoriasis
- conversion rate psoriasis patients
- secukinumab in patients efficacy and safety
- efficacy and safety latent tuberculosis
- analysis of subgroups secukinumab for psoriasis
- pooled phase latent tuberculosis
- patients with psoriasis concurrent hepatitis
- ankylosing spondylitis tuberculosis reactivation
- patients with psoriasis ankylosing spondylitis